Gut Brain Axis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
The Gut-Brain Axis (GBA), more precisely the microbiota-Gut-Brain Axis (MGBA), is a bidirectional communication network linking the gastrointestinal tract and its resident [microbiome[/entities/[microbiome[/entities/[microbiome[/entities/[microbiome[/entities/[microbiome--TEMP--/entities)--FIX-- with the central nervous system (CNS). This complex signaling system operates through neural, endocrine, immune, and metabolic pathways, enabling the gut microbiota to influence brain function, behavior, and neuroinflammatory states. Emerging evidence implicates Gut-Brain Axis dysregulation as a contributing factor in the pathogenesis of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, and other [neurodegenerative conditions[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, opening promising avenues for microbiome-targeted therapeutic interventions (Wang et al., 2024; Li & Mou, 2025). [2]
The gut and brain communicate through multiple neural routes:
- Vagus nerve: The primary neural conduit of the Gut-Brain Axis. The vagus nerve (cranial nerve X) carries approximately 80% afferent (gut-to-brain) and 20% efferent (brain-to-gut) fibers. Vagal afferents detect microbial metabolites, gut hormones, and inflammatory signals in the intestinal wall and relay this information to the [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- nucleus tractus solitarius (NTS), which projects to the [hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus--TEMP--/brain-regions)--FIX--, [amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--, and [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--.
- Enteric nervous system (ENS): Often called the "second brain," the ENS contains approximately 500 million [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- that control gut motility, secretion, and blood flow independently of the CNS. The ENS communicates with the brain through both vagal and spinal afferent pathways.
- Spinal afferents: Additional neural pathways transmitting visceral sensory information to the dorsal horn of the [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX--, providing complementary signaling to the vagal pathway. [3]
- Hypothalamic-pituitary-adrenal (HPA) axis: The central stress response system. Chronic stress leads to HPA axis dysregulation, resulting in elevated cortisol levels that can impair hippocampal function and promote [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--. This mechanism is particularly relevant in AD, where hippocampal atrophy is a hallmark finding.
- Gut hormones: GLP-1, PYY, ghrelin, and other gut-derived peptides affect satiety, energy homeostasis, and cognitive function. [GLP-1 receptor agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX-- have shown promise in preclinical AD models for reducing amyloid pathology and improving cognitive function (Li & Mou, 2025).
- Serotonin: Approximately 95% of the body's [serotonin[/entities/[serotonin[/entities/[serotonin[/entities/[serotonin[/entities/[serotonin--TEMP--/entities)--FIX-- is produced in the gut by enterochromaffin cells. Gut microbiota modulate serotonin synthesis, influencing mood, cognition, and gastrointestinal function. [4]
- Gut-associated lymphoid tissue (GALT): The largest immune organ in the body, containing approximately 70% of the body's immune cells. GALT samples luminal antigens and coordinates immune responses between the gut mucosa and systemic circulation.
- Cytokine signaling: Pro-inflammatory cytokines including IL-1-beta, IL-6, and TNF-alpha produced by gut immune cells can cross the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- and activate [microglia[/cell-types/microglia.[/cell-types/microglia.[/cell-types/microglia.[/cell-types/microglia.--TEMP--/cell-types)--FIX--
- Lipopolysaccharide (LPS): A cell wall component of gram-negative bacteria. Gut dysbiosis and increased intestinal permeability ("leaky gut") allow LPS to enter systemic circulation, where it activates [TLR4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4--TEMP--/entities)--FIX-- on [microglia[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX-- of neurodegeneration ([p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--.
- Intestinal barrier dysfunction ("leaky gut" and [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breakdown] create a dual-barrier failure that facilitates systemic inflammation reaching the brain. [5]
Clinical observations:
- Gastrointestinal symptoms often precede cognitive symptoms in AD.
- Patients with inflammatory bowel disease have increased AD risk in epidemiological studies.
- Long-term antibiotic use is associated with altered AD risk, supporting a microbial contribution to disease pathogenesis. [6]
The Gut-Brain Axis plays a particularly prominent role in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, where gastrointestinal dysfunction is one of the earliest prodromal features: [7]
- Braak's dual-hit hypothesis: [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- pathology may originate in the enteric nervous system and propagate to the brain via the vagus nerve, consistent with the bottom-up pattern of [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX--.
- Vagotomy and PD risk: Full truncal vagotomy is associated with reduced PD risk in epidemiological studies, supporting the vagal transmission hypothesis.
- Constipation as a prodromal symptom: Constipation precedes motor symptoms by up to 20 years in many PD patients, reflecting early ENS alpha.
- [Microbiome[/entities/[microbiome[/entities/[microbiome[/entities/[microbiome[/entities/[microbiome--TEMP--/entities)--FIX-- alterations: PD patients show characteristic changes including reduced Prevotella and increased Enterobacteriaceae, correlating with motor symptom severity (Nie et al., 2025).
- Indoxyl sulfate: This gut-derived uremic toxin is elevated in PD and associated with cognitive decline and worsening neurodegeneration. [8]
Emerging evidence links gut dysbiosis to [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--:
- [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- mutant mice show altered gut microbiome composition prior to symptom onset.
- Butyrate-producing bacteria are depleted in ALS patients, and butyrate supplementation delays disease progression in mouse models.
- Gut permeability is increased in ALS patients, potentially contributing to systemic inflammation. [9]
Gut microbiome alterations in [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- include:
- Reduced commensal bacteria that promote Treg differentiation.
- Increased pro-inflammatory taxa that drive Th17 polarization.
- Altered SCFA profiles affecting [oligodendrocyte[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX-- function and [demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination--TEMP--/mechanisms)--FIX--. [10]
Preliminary evidence suggests gut dysbiosis in [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, with altered microbiome composition and increased gut permeability in HD mouse models, though human data remain limited. [1]
¶ Probiotics and Prebiotics
Modulation of the gut microbiome with beneficial bacteria represents an accessible therapeutic approach: [2]
- Probiotics: Bifidobacterium and Lactobacillus species have shown anti-inflammatory effects and modest cognitive improvements in early clinical trials. The probiotic cocktail VSL#3 reduced [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- markers in preclinical AD models.
- Prebiotics: Dietary fiber supplements (inulin, fructo-oligosaccharides, galacto-oligosaccharides) promote SCFA-producing bacteria and enhance gut barrier integrity.
- Synbiotics: Combined probiotic-prebiotic formulations aim to maximize microbiome modulation. [3]
FMT, the transfer of stool from a healthy donor to a recipient, has been investigated as a direct approach to restore gut microbiome composition: [4]
- GUT-PARFECT trial (2024): This randomized, double-blind, placebo-controlled Phase 2 trial demonstrated that a single nasojejunal FMT induced mild but long-lasting beneficial effects on motor symptoms in early-stage [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- patients (Ghent University, 2024).
- Finnish randomized trial (2024): A separate double-blind, placebo-controlled trial in PD patients found FMT was safe but did not show clinically meaningful improvements in motor or non-motor outcomes (Noponen et al., 2024).
- Meta-analysis (2025): A systematic review of randomized controlled trials concluded that FMT showed no significant overall therapeutic effect on PD motor and non-motor symptoms compared to placebo, though individual responses varied (Wang et al., 2025).
- AD models: FMT from healthy donors to AD mouse models improved cognitive function and reduced amyloid pathology, though human clinical trials for AD remain in early stages. [5]
Diet is one of the strongest modulators of gut microbiome composition:
- Mediterranean diet: Associated with increased microbial diversity, higher SCFA production, reduced gut inflammation, and lower AD risk. Rich in fiber, polyphenols, and omega-3 fatty acids that promote beneficial gut bacteria.
- Ketogenic diet: May modulate gut-brain signaling through altered bile acid metabolism and increased SCFA production, with preliminary evidence for cognitive benefits in AD.
- MIND diet: Hybrid Mediterranean-DASH diet specifically designed for neuroprotection, with documented microbiome-modulating effects.
- Fiber supplementation: Increases butyrate-producing bacteria and strengthens gut barrier integrity. [6]
[Vagus nerve stimulation[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation--TEMP--/treatments)--FIX-- (VNS) modulates gut-brain communication: [7]
- Non-invasive transcutaneous VNS devices are being explored as a treatment for AD-related cognitive decline.
- VNS has anti-inflammatory effects mediated through the cholinergic anti-inflammatory pathway, reducing systemic and CNS inflammation. [8]
[GLP-1 receptor agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX-- (semaglutide, liraglutide, exenatide) represent a promising gut-brain therapeutic approach: [9]
- Originally developed for diabetes, these drugs cross the [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- and have neuroprotective effects.
- Reduce [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--, improve [brain insulin signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling--TEMP--/entities)--FIX--, and enhance [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance in preclinical models.
- Multiple [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials are evaluating GLP-1 agonists for AD and PD. [10]
Selective modulation of pathogenic gut bacteria (e.g., rifaximin for gram-negative overgrowth) while preserving beneficial commensals is under investigation, though broad-spectrum antibiotic use remains a concern due to microbiome disruption. [1]
Gut microbiome profiling is being explored as a non-invasive biomarker for early detection of neurodegenerative diseases, particularly PD where gut changes precede motor symptoms by years. [2]
Individual variation in microbiome composition means therapeutic responses to probiotics and FMT are highly variable. Future approaches may involve personalized microbiome analysis to tailor interventions. [3]
Combined microbiome and metabolomics profiling allows identification of specific microbial metabolites driving neurodegeneration, enabling targeted therapeutic development. [4]
Genetically modified bacteria designed to produce specific neuroprotective metabolites (e.g., BDNF, SCFAs) or degrade neurotoxic compounds (e.g., TMAO) are in preclinical development. [5]
- [Microglia[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation[/treatments/[vagus-nerve-stimulation--TEMP--/treatments)--FIX--
The study of Gut Brain Axis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development. [6]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [7]
- [Li J, Mou H. Gut-Brain Axis and a systematic approach to [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- therapies. Brain Sci Adv. 2025;11(1:1-18. [DOI: 10.26599/BSA.2024.9050031)(https://journals.sagepub.com/doi/10.26599/BSA.2024.9050031)
- [Nie S, et al. Gut dysbiosis as a potential driver of [Parkinson]'s and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathogenesis. Front Neurosci. 2025;19:1600148. [DOI: 10.3389/fnins.2025.1600148]https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1600148/full)
- [GUT-PARFECT investigators. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: a double-blind, placebo-controlled, randomised, phase 2 trial. eClinicalMedicine. 2024;71:102563. [Link]https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)
- [Noponen N, et al. Fecal microbiota transplantation for treatment of Parkinson disease: a randomized clinical trial. JAMA Neurol. 2024;81(9]:925-933. PMID: 39073834
- [Wang X, et al. Safety and efficacy of fecal microbiota transplantation in the treatment of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: a systematic review of clinical trials. Front Neurosci. 2025;19:1639911. [DOI: 10.3389/fnins.2025.1639911]https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1639911/full)
- [Wu M, et al. Microbiota-Gut-Brain Axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Front Immunol. 2025;16:1508284. [PMC12436269]https://pmc.ncbi.nlm.nih.gov/articles/PMC12436269/)
- [Kalli EE, et al. The brain-gut axis, an important player in Alzheimer and Parkinson disease: a narrative review. J Clin Med. 2024;13(14]:4130. DOI: 10.3390/jcm13144130
- [Jia X, et al. Modulation of gut microbiota through dietary intervention in neuroinflammation and Alzheimer's and Parkinson's diseases. Nutrients. 2024;16(8]:1134. PMID: 38652236
- [Tang J, et al. Reverse engineering the Gut-Brain Axis and microbiome-metabolomics for symbiotic/pathogenic balance in neurodegenerative diseases. Gut Microbes. 2024;16(1]:2422468. DOI: 10.1080/19490976.2024.2422468
- [Zheng Y, et al. The microbiota-Gut-Brain Axis in mental and neurodegenerative disorders: opportunities for prevention and intervention. Front Aging Neurosci. 2025;17:1667448. [DOI: 10.3389/fnagi.2025.1667448]https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1667448/full) [10]
[4]